STME · XBRL financial data
StimCell Energetics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (STME's year ends in late May)
| In thousands of dollars | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|
| Revenue | — | — | 3 | 0 | — | — |
| Cost of goods and services sold | 3 | 2 | — | — | — | — |
| Gross profit | 4 | 4 | 0 | 0 | — | — |
| Research and development | 230 | 151 | 89 | — | — | — |
| General and administrative | 186 | 334 | 276 | 161 | 213 | 383 |
| Total operating expenses | 729 | 676 | 448 | 268 | 522 | 826 |
| Interest expense | 32 | 26 | 47 | 62 | 38 | 69 |
| Net income (loss) | (911) | (697) | — | — | — | — |
| Earnings per share, basic USD per share | (0.02) | (0.01) | (0.01) | 0.00 | (0.03) | (0.04) |
| Weighted average shares, basic thousands of shares | 58,764 | 62,799 | 62,923 | 161,008 | 19,843 | 20,747 |
Balance sheet
CSVFiscal years (STME's year ends in late May)
| In thousands of dollars | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 21 | 24 | 98 | 43 | 15 | 3 |
| Inventory | 0 | — | — | — | — | — |
| Total current assets | 51 | 41 | — | — | — | — |
| Property and equipment, net | 1 | 0 | — | — | — | — |
| Total assets | 52 | 41 | 103 | 46 | 21 | 81 |
| Accounts payable | 432 | 442 | 408 | 289 | 322 | 356 |
| Accrued liabilities | 35 | 29 | 37 | 28 | 27 | 38 |
| Total liabilities | 1,628 | 2,050 | 2,489 | 873 | 1,268 | 1,893 |
| Accumulated deficit | (8,960) | (9,658) | (10,153) | (10,295) | (10,862) | (11,757) |
| Total liabilities and equity | 52 | 41 | 103 | 46 | 21 | 81 |
| Common shares outstanding (cover page) thousands of shares | 62,923 | 62,923 | 62,923 | 297,236 | 20,516 | 21,141 |
Cash flows
CSVFiscal years (STME's year ends in late May)
| In thousands of dollars | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | May 31, 2025 | May 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (911) | (697) | — | — | — | — |
| Net cash from operating activities | (560) | (451) | (272) | (146) | (142) | (312) |
| Purchases of property and equipment | 2 | 0 | — | — | — | — |
| Net cash from investing activities | (2) | 0 | — | — | — | — |
| Proceeds from issuing equity | 207 | 160 | 0 | 75 | 0 | — |
| Net cash from financing activities | 535 | 454 | 346 | 91 | 113 | 301 |
| Net change in cash | (24) | 4 | 74 | (55) | (29) | (12) |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| INVO Fertility | 3,733 | 2,175 | (1,101)* | 2.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Nu-Med Plus | 5.4 | 0 | 1.1* | 83.5M | — | 10-QJun 30, 2026 |
| Vycor Medical | 159 | 418 | (4.8)* | 33.4M | 32.8 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.